VivoSim Labs, Inc. (LON:0R02)
3.174
+0.065 (2.09%)
At close: Mar 20, 2025
VivoSim Labs Revenue
VivoSim Labs had revenue of $37.00K USD in the quarter ending June 30, 2025, a decrease of -5.13%. This brings the company's revenue in the last twelve months to $142.00K, up 94.52% year-over-year. In the fiscal year ending March 31, 2025, VivoSim Labs had annual revenue of $144.00K with 32.11% growth.
Revenue (ttm)
$142.00K
Revenue Growth
+94.52%
P/S Ratio
70.58
Revenue / Employee
$10.92K
Employees
13
Market Cap
7.32M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 144.00K | 35.00K | 32.11% |
Mar 31, 2024 | 109.00K | -261.00K | -70.54% |
Mar 31, 2023 | 370.00K | -1.13M | -75.33% |
Mar 31, 2022 | 1.50M | - | - |
Mar 31, 2021 | - | - | - |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.35B |
HUTCHMED (China) | 439.54M |
Genus | 672.80M |
VivoSim Labs News
- 5 months ago - VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market - GlobeNewsWire
- 5 months ago - VivoSim to Carry Forward Organovo 3D Bioprinting - GlobeNewsWire
- 6 months ago - Organovo reports $11.3M cash balance in FY24 - Seeking Alpha
- 6 months ago - Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements - GlobeNewsWire
- 6 months ago - Organovo gets upfront payments following sale of its FXR Program to Lilly - Seeking Alpha
- 6 months ago - Organovo Provides Business Update - GlobeNewsWire
- 6 months ago - Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company - GlobeNewsWire
- 6 months ago - Organovo announces reverse stock split; shares fall - Seeking Alpha